Literature DB >> 6603301

Human B cell growth factors overcome T cell-mediated inhibition of specific antibody production: a possible mechanism for the exacerbation of autoimmune disease.

M K Brenner, M E North.   

Abstract

Under normal circumstances, antigen-dependent antibody production in man requires autologous T cells, B cells and macrophages. If allogeneic T cells are substituted, then antibodies are not synthesized, due to the development of inhibitory interactions. Addition of B cell growth and differentiation factors changes this pattern of response, and allows antibodies to be produced even when allogeneic T cells are the source of help. There is evidence that such B cell growth factors are released during most normal immune responses: we suggest that their ability to allow B cells to escape from inhibitory interactions and secrete antibodies, may underlie the observed exacerbation of certain autoimmune diseases by intercurrent infection.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6603301      PMCID: PMC1536023     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  17 in total

1.  The production of a soluble human T-lymphocyte derived factor which substitutes for helper T lymphocytes in the in vitro production of immunoglobulin.

Authors:  R H Stevens; C J Thiele; A Saxon
Journal:  Immunology       Date:  1979-03       Impact factor: 7.397

2.  Induction of nonspecific, proliferative dependent suppressor T lymphocytes in human mixed lymphocyte cultures.

Authors:  J J Rinehart
Journal:  Cell Immunol       Date:  1980-11       Impact factor: 4.868

Review 3.  Hypothesis: nonspecific polyclonal activation of memory B cells by antigen as a mechanism for the preservation of long term immunologic anamnesis.

Authors:  E J Moticka; J W Streilein
Journal:  Cell Immunol       Date:  1978-12       Impact factor: 4.868

Review 4.  Conditions determining the generation and expression of T helper cells.

Authors:  H Waldmann
Journal:  Immunol Rev       Date:  1977       Impact factor: 12.988

5.  T lymphocyte-mediated suppression of myeloma function in vitro. I. Suppression by allogeneically activated T lymphocytes.

Authors:  A K Abbas
Journal:  J Immunol       Date:  1979-11       Impact factor: 5.422

6.  A human soluble suppressor factor affecting lymphocyte responses in vitro.

Authors:  L Shou; S A Schwartz; R A Good; R Peng; C L Chen
Journal:  Proc Natl Acad Sci U S A       Date:  1980-10       Impact factor: 11.205

7.  In vitro studies on H-2-linked unresponsiveness to synthetic polypeptides. III. Production of an antigen-specific T helper cell factor to (T,G)-A--L.

Authors:  S Howie; M Feldman
Journal:  Eur J Immunol       Date:  1977-07       Impact factor: 5.532

8.  Induction of polyclonal antibody synthesis by human allogeneic and autologous helper factors.

Authors:  N Chiorazzi; S M Fu; H G Kunkel
Journal:  J Exp Med       Date:  1979-06-01       Impact factor: 14.307

9.  Antigen-specific helper factor in man.

Authors:  F B Mudawwar; E J Yunis; R S Geha
Journal:  J Exp Med       Date:  1978-10-01       Impact factor: 14.307

10.  Development of allergy in children. I. Association with virus infections.

Authors:  O L Frick; D F German; J Mills
Journal:  J Allergy Clin Immunol       Date:  1979-04       Impact factor: 10.793

View more
  3 in total

1.  Rapid recovery of helper activity following T cell depleted allogeneic marrow transplant.

Authors:  J Z Wimperis; M K Brenner; H G Drexler; A V Hoffbrand; H G Prentice
Journal:  Clin Exp Immunol       Date:  1987-09       Impact factor: 4.330

2.  Enhanced T helper cell function for the spontaneous production of IgM rheumatoid factor in vitro in rheumatoid arthritis.

Authors:  V Patel; G S Panayi
Journal:  Clin Exp Immunol       Date:  1984-06       Impact factor: 4.330

3.  Cooperation between major histocompatibility complex mismatched mononuclear cells from a human chimera in the production of antigen-specific antibody.

Authors:  M G Roncarolo; J L Touraine; J Banchereau
Journal:  J Clin Invest       Date:  1986-03       Impact factor: 14.808

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.